Vaccination strategies for an influenza pandemic

Journal of Infectious Diseases

Volumn 191, Issue 8, 2005, Pages 1207-1209

  Schwartz, Benjamin ^a,b   Gellin, Bruce ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VIRUS ANTIGEN;

ANIMAL MODEL; ANTIGENIC DRIFT; CELL CULTURE; DRUG FORMULATION; DRUG INDUSTRY; EPIDEMIC; EVOLUTION; GENE MUTATION; GENETIC DRIFT; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LICENSING; NONHUMAN; NOTE; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; TIME FACTORS; VACCINATION;

EID: 17044390957     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428952     Document Type: Note

References (15)

1. Stohr K, Esveld M. Will vaccines be available for the next influenza pandemic? Science 2004; 306:2195-6.
2. Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005; 191:1216-20 (in this issue).
3. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-5 (in this issue).
4. World Health Organization. Vaccines for pandemic influenza. Available at: http://www.who.int/csr/resources/publications/influenza/en/vaccinpandemicinflu. pdf. Accessed 4 January 2005.
5. US National Institute of Allergy and Infectious Diseases. Development of a clinical trial plan for pandemic influenza vaccines. Available at: http://www.niaid.nih.gov/dmid/meetings/fluvaccine.htm. Accessed 4 January 2005.
6. Federal Business Opportunities. Q-cell-based monovalent pandemic influenza vaccine, 2004-N-011002. Available at: http://www2.eps.gov/servlet/ Documents/R/271592/475313. Accessed 4 January 2005.
7. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71.
8. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002; 191:203-8.
9. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am 2003; 23:787-813.
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301.
11. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94.
12. US Department of Health and Human Services. Pandemic influenza response and preparedness plan. Available at: http://www.hhs.gov/nvpo/pandemicplan. Accessed 4 January 2005.
13. US Department of Health and Human Services. NIH news. Available at: http://www2.niaid.nih.gov/newsroom/Releases/flucontracts.htm. Accessed 4 January 2005.
14. US Department of Health and Human Services. NIH news release: NNS orders avian flu vaccine doses as preventive measure. Available at: http://www.hhs.gov/news/press/2004pres/20040921a.html. Accessed 4 January 2005.
15. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004 conference. Available at: http://www.who.int/ vaccine_research/documents/infl_feb04/en/index2.html. Accessed 8 March 2005.